Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Age-related macular degeneration (AMD) is the most common form of irreversible blindness in developed countries. Variants in the factor H gene (CFH, also known as HF1), which encodes a major inhibitor of the alternative complement pathway, are associated with the risk for developing AMD. Here we test the hypothesis that variation in genes encoding other regulatory proteins of the same pathway is associated with AMD. We screened factor B (BF) and complement component 2 (C2) genes, located in the major histocompatibility complex class III region, for genetic variation in two independent cohorts comprising approximately 900 individuals with AMD and approximately 400 matched controls. Haplotype analyses identify a statistically significant common risk haplotype (H1) and two protective haplotypes. The L9H variant of BF and the E318D variant of C2 (H10), as well as a variant in intron 10 of C2 and the R32Q variant of BF (H7), confer a significantly reduced risk of AMD (odds ratio = 0.45 and 0.36, respectively). Combined analysis of the C2 and BF haplotypes and CFH variants shows that variation in the two loci can predict the clinical outcome in 74% of the affected individuals and 56% of the controls. These data expand and refine our understanding of the genetic risk for AMD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This analysis resulted in the identification of the previously well documented independently associated variants near CFH and C2/CFB8,10,31,32 and of additional independent signals near C3, CETP, LIPC, FRK/COL10A1, IER3/DDR1, RAD51B (Supplementary Table 6).”
From Seven new loci associated with age-related macular degeneration (2013) · cites this paper as [8]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Genes in the complement pathway4–11 and a region of chromosome 10 12,13 have now been implicated as the major genetic contributors to disease.”
From Seven new loci associated with age-related macular degeneration (2013) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“These include complement 2 (C2) and/or complement factor B (CFB) (56), complement 3 (C3) (170), and complement factor I (CFI) (44).”
From Unraveling a Multifactorial Late-Onset Disease: From Genetic Susceptibility to Disease Mechanisms for Age-Related Macular Degeneration (2009) · cites this paper as [56]
In the citing paper
“studies have demonstrated that at least one of the two variants associated with AMD—R32Q BF—leads to an impairment in the complement activating function of BF (Gold et al., 2006).”
From Molecular pathology of age-related macular degeneration (2009) · cites this paper as Gold et al., 2006
In the citing paper
“the L9H BF/E318D C2 and R32Q BF/intronic variants of C2 have been shown to be protective for AMD (odds ratio (OR) = 0.45 and 0.36, respectively) by Gold et al.”
From Molecular pathology of age-related macular degeneration (2009) · cites this paper as Gold et al., 2006
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482 · cited 1×
“Overall type I error rates (α) were retrospectively calculated using a previously described metho”
MethodComplement factor H polymorphism in age-related macular degeneration
Klein, R. J., Zeiss, C., Chew, E. Y., Tsai, J.-Y., Sackler, R. S., Haynes, C., Henning, A. K., SanGiovanni, J. P., Mane, S. M., Mayne, S. T., et al. (2005) · Science · doi:10.1126/science.1109557 · Cited by 4,492
Complement factor H polymorphism and age-related macular degeneration
Edwards, A. O., Ritter, R., Abel, K. J., Manning, A., Panhuysen, C., & Farrer, L. A. (2005) · Science · doi:10.1126/science.1110189 · Cited by 2,449
Complement factor H variant increases the risk of age-related macular degeneration
Haines, J. L., Hauser, M. A., Schmidt, S., Scott, W. K., Olson, L. M., Gallins, P., Spencer, K. L., Kwan, S. Y., Noureddine, M., Gilbert, J. R., et al. (2005) · Science · doi:10.1126/science.1110359 · Cited by 2,424
Hageman, G. S., Anderson, D. H., Johnson, L. V., Hancox, L. S., Taiber, A. J., Hardisty, L. I., Hageman, J. L., Stockman, H. A., Borchardt, J. D., Gehrs, K. M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501536102 · Cited by 1,961
Self-citationBird, A. C., Bressler, N. M., Bressler, S. B., Chisholm, I. H., Coscas, G., Davis, M. D., de Jong, P. T. V. M., Klaver, C. C. W., Klein, B. E. K., Klein, R., et al. (1995) · Survey of Ophthalmology · doi:10.1016/s0039-6257(05)80092-x · Cited by 1,926
Hageman, G. (2001) · Progress in Retinal and Eye Research · doi:10.1016/s1350-9462(01)00010-6 · Cited by 1,265
Self-citationDrusen proteome analysis: an approach to the etiology of age-related macular degeneration
Crabb, J. W., Miyagi, M., Gu, X., Shadrach, K., West, K. A., Sakaguchi, H., Kamei, M., Hasan, A., Yan, L., Rayborn, M. E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.222551899 · Cited by 1,208
A Fine-Scale Map of Recombination Rates and Hotspots Across the Human Genome
Myers, S., Bottolo, L., Freeman, C., McVean, G., & Donnelly, P. (2005) · Science · doi:10.1126/science.1117196 · Cited by 1,134 · cited 1×
“Fourth, estimated recombination rates from HapMap data indicate regions of high recombination on both sides of the C2/BF locu”
BackgroundA role for local inflammation in the formation of drusen in the aging eye
Anderson, D. H., Mullins, R. F., Hageman, G. S., & Johnson, L. V. (2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(02)01624-0 · Cited by 1,087
Self-citationMullins, R. F., Russell, S. R., Anderson, D. H., & Hageman, G. S. (2000) · The FASEB Journal · doi:10.1096/fasebj.14.7.835 · Cited by 937
Self-citationThe epidemiology of age-related macular degeneration
Klein, R., Peto, T., Bird, A., & Vannewkirk, M. R. (2004) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2003.11.069 · Cited by 932 · cited 1×
“dtd" [ ]> Age-related macular degeneration (AMD) is the most common form of irreversible blindness in developed countrie”
Mutation of the Stargardt Disease Gene ( ABCR ) in Age-Related Macular Degeneration
Allikmets, R., Shroyer, N. F., Singh, N., Seddon, J. M., Lewis, R. A., Bernstein, P. S., Peiffer, A., Zabriskie, N. A., Li, Y., Hutchinson, A., et al. (1997) · Science · doi:10.1126/science.277.5333.1805 · Cited by 880 · cited 1×
“PCR-derived amplicons were screened for sequence variation, as described earlie”
MethodSelf-citationJohnson, L. V., Leitner, W. P., Staples, M. K., & Anderson, D. H. (2001) · Experimental Eye Research · doi:10.1006/exer.2001.1094 · Cited by 621
Zareparsi, S., Branham, K. E. H., Li, M., Shah, S., Klein, R. J., Ott, J., Hoh, J., Abecasis, G. R., & Swaroop, A. (2005) · The American Journal of Human Genetics · doi:10.1086/431426 · Cited by 371
Incidence and progression rates of age-related maculopathy: the Rotterdam Study.
Klaver, C. C. W., Assink, J. J. M., van Leeuwen, R., Wolfs, R. C. W., Vingerling, J. R., Stijnen, T., Hofman, A., & de Jong, P. T. (2001) · EUR Research Repository (Erasmus University Rotterdam) · Cited by 353
Complement deficiency and disease
Morgan, B. P., & Walport, M. J. (1991) · Immunology Today · doi:10.1016/0167-5699(91)90003-c · Cited by 302
(2016) · Juntendo Medical Journal · doi:10.14789/jmj.62.54 · Cited by 295
Complete MHC Haplotype Sequencing for Common Disease Gene Mapping
Stewart, C. A., Horton, R., Allcock, R. J. N., Ashurst, J. L., Atrazhev, A. M., Coggill, P., Dunham, I., Forbes, S., Halls, K., Howson, J. M. M., et al. (2004) · Genome Research · doi:10.1101/gr.2188104 · Cited by 285 · cited 1×
“Moreover, no additional nonsynonymous variants in either gene have been found after complete sequencing of several MHC haplotypes, including examples of our haplotypes H2, H5, and H7 (ref”
BackgroundBiology of complement: the overture
Kinoshita, T. (1991) · Immunology Today · doi:10.1016/0167-5699(91)90001-a · Cited by 214 · cited 1×
“Dysfunction of the complement pathway is proposed to induce significant damage to macular cells, leading to atrophy, degeneration and the elaboration of choroidal neovascular membrane”
BackgroundREVIEW: Epidemiology of age-related maculopathy: a review
van Leeuwen, R., Klaver, C. C. W., Vingerling, J. R., Hofman, A., & de Jong, P. T. V. M. (2003) · European Journal of Epidemiology · doi:10.1023/a:1025643303914 · Cited by 191
Conley, Y. P., Thalamuthu, A., Jakobsdottir, J., Weeks, D. E., Mah, T., Ferrell, R. E., & Gorin, M. B. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi204 · Cited by 158
Evidence for an inflammatory process in age-related macular degeneration gains new support
Bok, D. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502819102 · Cited by 129
The genetics of HLA-associated disease
Larsen, C. E., & Alper, C. A. (2004) · Current Opinion in Immunology · doi:10.1016/j.coi.2004.07.014 · Cited by 103 · cited 1×
“Because C2 and BF reside in the MHC locus with many other genes involved in inflammation, it is possible that the associations observed in this study are due to LD with adjacent loc”
BackgroundThe alternative pathway of complement in disease: opportunities for therapeutic targeting
Holers, V. M., & Thurman, J. M. (2004) · Molecular Immunology · doi:10.1016/j.molimm.2004.03.012 · Cited by 93 · cited 1×
“Dysfunction of the complement pathway is proposed to induce significant damage to macular cells, leading to atrophy, degeneration and the elaboration of choroidal neovascular membrane”
BackgroundAssociation of HLA Class I and Class II Polymorphisms with Age-Related Macular Degeneration
Goverdhan, S. V., Howell, M. W., Mullins, R. F., Osmond, C., Hodgkins, P. R., Self, J., Avery, K., & Lotery, A. J. (2005) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.04-0928 · Cited by 78
Alper, C. A., Xu, J., Cosmopoulos, K., Dolinski, B. M., Stein, R., Uko, G., Larsen, C. E., Dubey, D. P., Densen, P., Truedsson, L., et al. (2003) · Journal of Clinical Immunology · doi:10.1023/a:1024540917593 · Cited by 44 · cited 1×
“Several common functional variants in both C2 and BF have been describe”
BackgroundHayashi, M., Merriam, J. E., Klaver, C. C. W., Zernant, J., Bergen, A. A. B., Smith, R. T., Chang, S., Merriam, J. C., & Allikmets, R. L. (2004) · Ophthalmic Genetics · doi:10.1080/13816810490514342 · Cited by 43 · cited 1×
“PCR-derived amplicons were screened for sequence variation, as described earlie”
MethodSelf-citationRaum, D. D., Glass, D. N., Carpenter, C. B., Schur, P. H., & Alper, C. A. (1979) · Europe PMC (PubMed Central) · Cited by 37
Lokki, M., & Koskimies, S. (1991) · Immunogenetics · doi:10.1007/bf00215259 · Cited by 35
Ca, D., & Forristal, J. (1980) · PubMed · Cited by 18
Cited by
A global reference for human genetic variation
The 1000 Genomes Project Consortium, authors, C., Auton, A., Abecasis, G. R., Steering committee, Altshuler, D. M., Durbin, R. M., Abecasis, G. R., Bentley, D. R., Chakravarti, A., et al. (2015) · Nature · doi:10.1038/nature15393 · Cited by 18,247
Self-citationAge-related macular degeneration
Jager, R. D., Mieler, W. F., & Miller, J. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0801537 · Cited by 1,379
Complement regulators and inhibitory proteins
Zipfel, P. F., & Skerka, C. (2009) · Nature Reviews Immunology · doi:10.1038/nri2620 · Cited by 1,264
“The affected genes encode C3 and factor B (the two components of C3 convertase) or the regulators of C3 convertase factor H, CD46 and factor I”
BackgroundThe impact of oxidative stress and inflammation on RPE degeneration in non-neovascular AMD
Datta, S., Cano, M., Ebrahimi, K., Wang, L., & Handa, J. T. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.03.002 · Cited by 802
“…in other complement pathway genes that influence the risk for AMD were identified such as C3 (rs2230199), factor I (rs10033900), and the C2/factor B locus (rs9332739, rs547154, rs4151667, and rs641153) (Fagerness et al., 2009; Gold et al., 2006; Spencer et al., 2007; Yates et al., 2007).”
BackgroundComplement C3 variant and the risk of age-related macular degeneration
Yates, J. R. W., Sepp, T., Matharu, B. K., Khan, J. C., Thurlby, D. A., Shahid, H., Clayton, D. G., Hayward, C., Morgan, J., Wright, A. F., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072618 · Cited by 829
Metadata
- Authors
- The AMD Genetics Clinical Study Group, Gold, B., Merriam, J. E., Zernant, J., Hancox, L. S., Taiber, A. J., Gehrs, K., Cramer, K., Neel, J., Bergeron, J., Barile, G. R., Smith, R. T., Hageman, G. S., Dean, M., & Allikmets, R.
- Affiliations
- National Cancer Institute (US)
- Columbia University (US)
- University of Iowa (US)
- Science Applications International Corporation (United States) (US)
- Corresponding author
- Dean, Michael
- Allikmets, Rando
- ORCID
- Venue
- Nature Genetics
- Published
- 2006-03-05
- Volume
- 38
- Issue
- 4
- Pages
- 458-462
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- PMC
- PMC2921703
- OpenAlex
- W1997288094
- Cited by
- 1,075
- References
- 31
- Citations by year
- 2026: 17 · 2025: 17 · 2024: 18 · 2023: 17 · 2022: 27 · 2021: 40 · 2020: 33 · 2019: 28 · 2018: 27 · 2017: 31 · 2016: 47 · 2015: 65 · 2014: 74 · 2013: 69 · 2012: 90
- FWCI
- 85.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Eye Institute (EY11515, R01EY013435, EY-13435, R01EY015520, R01EY011515)
- National Cancer Institute (N01-CO-124000)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- age-related macular degeneration, factor B, alternative complement pathway, genetic risk variants, haplotypes, complement factor H, MHC class III, genetic susceptibility
- MeSH terms
- Aged, Aged, 80 and over, Aging, Chromatography, High Pressure Liquid, Complement C2, Haplotypes, Humans, Immunohistochemistry, Macular Degeneration, Molecular Sequence Data, Complement Factor B, Cohort Studies, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.